Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn’s Disease Patients
SAN DIEGO, Sept. 14, 2022 /PRNewswire/ — Prometheus Laboratories Inc. (“Prometheus”) today announced its partnership with Takeda Pharmaceutical Company Limited (“Takeda”) to nationally launch CDPATH, an innovative prognostic tool for Crohn’s disease (CD) patients. CDPATH is a…
Comments Off on Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn’s Disease Patients